SEC Form 4 · accession 0001225208-18-009683
Edwards Lifesciences Corp · EW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Huimin Wang
Officer — CVP, Japan & Intercontinental
Period of report
May 17, 2018
Accepted (ET)
May 21, 2018 · 8:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001099800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 17, 2018 | A | 1,325 | $0.00 | A | 84,588 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Acquire)F2 | $135.83 | May 17, 2018 | A | 13,000 | A | Jun 17, 2018 | May 16, 2025 | Common Stock | 13,000 | 13,000 | D |
| Performance RightsF3 | — | May 17, 2018 | A | 1,650 | A | May 17, 2021 | May 16, 2025 | Common Stock | 1,650 | 1,650 | D |
Explanation of responses
- F1These restricted stock units were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date.
- F2These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal annual installments.
- F3Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.